As Chief Scientific Officer and President, Research & Development, for Pfizer, Inc., Chris Boshoff leads the company’s research and development strategy and execution in all Therapeutic Areas, including Inflammation & Immunology, Internal Medicines, Oncology and Vaccines, and is responsible for Pfizer’s Medical Affairs, Safety, Global Regulatory, Pharmaceutical Sciences, Clinical Operations, and both large and small molecule discovery.

Prior to this role, Chris served as Chief Oncology Officer, where he was accountable for end-to-end cancer drug discovery, Clinical Development, Medical Affairs and Commercialization. He oversaw Pfizer’s research and development hubs in La Jolla, CA and Seattle, WA; for all global clinical development activities in Oncology from Phase 1 to Phase IV; for Oncology Medical Affairs and for the US commercialization and access for patients with cancer to Pfizer’s portfolio of over 25 approved cancer medicines.

Before joining Pfizer over a decade ago, Chris served for several years as founding Director of the University College London (UCL) Cancer Institute, London, U.K.

Chris earned his PhD from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London. Throughout his career, he has published over 150 original articles covering cancer biology, tumor virology and experimental cancer medicine. He contributed to the early foundational discoveries related to Kaposi’s sarcoma-associated herpesvirus (KSHV).